BASIC SCIENCE RESEARCH PROGRAM
Innovative Techniques Through Basic Science Research
The Basic Science Research Program (BSRP) focuses on defining prostate cancer-specific molecular alterations that would lead to better understanding of the causes of prostate cancer. Prostate cancer gene discovery and biology focused research efforts are complemented by collaborations from the CPDR's Clinical Research and Multicenter National Database programs, accelerating the evaluations of new biomarkers and therapeutic targets with potential in enhancing the management of prostate cancer.
The program is led by Dr. Shiv Srivastava, who is an internationally recognized leader in the field of cancer research. Strong collaborations with Dr. Isabell A. Sesterhenn from JPC (formerly AFIP) and the CPDR-Clinical Research Program at WRNMMC (formerly WRAMC) remains the mainstay of the highly productive translational research initiatives. Due to the reorganization of the AFIP as JPC, Dr. Sesterhenn's laboratory has been integrated within the CPDR-BSRP as of August 2011.
- Discovery of frequent and potentially causal prostate cancer gene alterations using cutting edge technologies and well annotated and precisely processed bio-specimens
- Evaluation of cancer biology of prostate cancer relevant genes or proteins using established and new experimental models
- Development of new molecular strategies for improving prostate cancer diagnosis (more cancer specific markers than PSA) and prognosis Contents are Proprietary and Provided for CPDR Scientific Advisory Committee Review Only 1: 5
- Delineation of hormonal mechanisms involved in prostate cancer onset or progression
- Development and evaluation of novel molecular therapeutic agents for prostate cancer
- Identification of molecular determinants of prostate cancer susceptibility in high-risk groups such as African-Americans
- Development and maintenance of long-term molecular specimen resources for translational investigations at CPDR and collaborations at other institutions
- Education and training of next generation of basic science and translational researchers in prostate cancer
Education and training of medical and graduate students, post-doctoral fellows, residents and visiting scientists in CaP research Two of the major activities of the BRP research program include investigator-initiated research and development of unique bio-resources critical for research at CPDR and in the CaP field.
August 21, 2014
ERG Monoclonal Antibody [9FY] Patent Issued To The Uniformed Services University Of The Health Sciences Center For Prostate Disease Research & Biocare Medical
Concord, CA – The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has been awarded a patent in the United States (Patent No: US 8,765,916 B2) and Europe for ERG monoclonal antibodies. The patent is pending in Australia, Canada and Japan. ERG mouse antibody 9FY is a rigorously characterized antibody for its specificity of the ERG protein detection among the closely related members of the ETS transcription factor family in biological specimens.
Read Full Article
August 6, 2014
Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints
Redwood City, CA – PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer. This study validated the Oncotype DX prostate cancer test as a ...
Read Full Article
WRNMMC UsToo! Newsletter
Read the AUGUST 2014 Newsletter